Showing 871-880 of 3305 results for "".
- Cynosure to Be Acquired by Hologichttps://modernaesthetics.com/news/cynosure-to-be-acquired-by-hologic/2472278/Hologic, Inc. and Cynosure, Inc. have signed a definitive agreement for Hologic to acquire all outstanding Cynosure shares for $66.00 per share in cash, which corresponds to an equity value of approximately $1.65 billion
- Allergan Agrees to Acquire ZELTIQ for $2.47 Billionhttps://modernaesthetics.com/news/allergan-agrees-to-acquire-zeltiq-for-247-billion/2472280/Allergan plc and ZELTIQ® Aesthetics, Inc. have entered into a definitive agreement under which Allergan has agreed to acquire ZELTIQ for $56.50 per share, or $2.475 billion, subject to customary
- Allergan Launches Juvéderm Volitehttps://modernaesthetics.com/news/allergan-launches-juvderm-volite/2472287/Allergan plc launched Juvéderm Volite, an injectable product specifically designed to improve skin quality and last up to nine months with just one treatment session. This innovative new Allergan product uses the unique patented Vycross technology. The new HA injectable treatment d
- Aesthetics Wire Exclusive: AAFPRS Survey Shows Combination Facial Plastic Surgery Treatment Requests Are Soaringhttps://modernaesthetics.com/news/aesthetics-wire-exclusivecombination-facial-plastic-surgery-treatment-requests-soaring/2472289/Combination therapies reign supreme, according to the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) 2016 statistics. In 2016, 66 percent of facial plastic surgeons reported performing combined non-surgical procedures in the same
- FDA Approves Restylane Refyne and Restylane Defyne Dermal Fillers for “Laugh Lines”https://modernaesthetics.com/news/fda-approves-restylane-refyne-and-restylane-defyne-dermal-fillers-for-laugh-lines/2472303/The FDA has approved two new Galderma products for the treatment of nasolabial folds (NLF) or “laugh lines,” in patients over the age of 21. Restylane Refyne was approved for the treatment of moderate to severe facial wrinkles and folds and Restylane®
- AAD Selects ContextMedia:Health as Patient Education Affinity Partnerhttps://modernaesthetics.com/news/aad-selects-contextmediahealth-as-patient-education-affinity-partner/2472318/ContextMedia:Health is now an Affinity Partner with the American Academy of Dermatology (AAD). The partnership offers ContextMedia:Health's suite of digital technology to the AAD's U.S. members at no cost. The agreement also bring
- Recently Retired American Academy of Facial Plastic and Reconstructive Surgery CEO Receives AMA Lifetime Achievement Awardhttps://modernaesthetics.com/news/recently-retired-american-academy-of-facial-plastic-and-reconstructive-surgery-ceo-receives-ama-lifetime-achievement-award/2472317/The American Medical Association (AMA) has presented the Medical Executive Lifetime Achievement Award to Stephen C. Duffy, former executive vice president and CEO of the American Academy of Facial Plastic and Reconstructive Sur
- Syneron Candela's Profound SubQ FDA Approved to Improve Cellulitehttps://modernaesthetics.com/news/syneron-candelas-profound-subq-fda-approved-to-improve-cellulite/2472321/Syneron Candela received FDA 510(k) clearance for Profound when using the SubQ handpiece and cartridge to improve the appearance of cellulite in patients with Fitzpatrick skin types I-III, as supported by long term data (6 months). A recent multi-center clinical study of Profound sh
- New Study Supports Combined Approach for Facial Rejuvenationhttps://modernaesthetics.com/news/new-study-supports-combined-approach-for-facial-rejuvenation/2485450/New research in the Journal of Cosmetic Dermatology supported the use of combined radiofrequency microneedling (RFMN) and 1927 nm thulium (Tm) laser treatment versus RFMN monotherapy for lower face and neck rejuvenation in photoaged skin.
- Analysis: PBoNT/A and ABoNT/A Show Fastest Onset in Glabellar Line Treatmenthttps://modernaesthetics.com/news/analysis-pbonta-and-abonta-show-fastest-onset-in-glabellar-line-treatment/2475374/A newly published study reports the comparative effects of four botulinum toxin A (BoNT/A) formulations on glabellar strain, with observed differences in onset, longevity, and muscular strain patterns. Researchers pu